Rosenkranz B, Winkelmann BR, Parnham MJ. Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet 1996; 30 (5): 372-84
Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators: part II. Clin Pharmacokinet 1998; 35 (1): 9-36
Ignarroo LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84 (24): 9265-9
Hug J, Hasenfuss G, Wollschlager H, et al. Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration [in German]. Med Klin 1994; 89 Suppl. 2: 34-7
Munzel T, Kurz S, Heitzer T, et al. Effects of intravenous administration of nitroglycerin and SIN-1 or molsidomine on epicardial arterial diameter in patients with stable coronary heart disease [in German]. Med Klin 1994; 89 Suppl. 2: 38-41
Ostrowski J, Gaul G, Voegele D, et al. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease. Eur J Clin Pharmacol 1985; 28 (5): 611-3
Rietbrock S, Keller-Stanislawski B, Thurmann P, et al. Pharmacokinetic profile of a novel slow release preparation of molsidomine. Eur J Clin Pharmacol 1992; 43 (3): 273-6
Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multilayer matrix tablets containing drugs of different solubility. Biomaterials 1996; 17 (9): 889-96
Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int J Pharm 2000; 195 (1-2): 229-38
Frishman WH. A new extended-release formulation of diltiazem HCl for the treatment of mild-to-moderate hypertension. J Clin Pharmacol 1993; 33 (7): 612-22
McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62 (4): 633-53
Spertus JA, Dewhurst T, Dougherty CM, et al. Testing the effectiveness of converting patients to long-acting antianginal medications: the Quality of Life in Angina Research Trial (QUART). Am Heart J 2001; 141 (4): 550-8
Jansen R, Niemeyer MG, Cleophas TJ, et al. Factors influencing efficacy of nitrate therapy for stable angina pectoris: a multiple linear regression analysis. Angiology 2000; 51 (12): 1007-12
van Kesteren HA, Withagen AJ. A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris: Amlodipine Study Group. Cardiovasc Drugs Ther 1998; 12 Suppl. 3: 233-7
Chugh SK, Digpal K, Hutchinson T, et al. A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina. J Cardiovasc Pharmacol 2001; 38 (3): 356-64
Schug BS, Brendel E, Wonnemann M, et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 2002; 58 (2): 119-25
Fihn SD, Williams SV, Daley J, et al. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med 2001; 135 (8 Pt 1): 616-32
Wildgrube HJ, Ostrowski J, Chamberlain J, et al. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers. Arzneimittel Forschung 1986; 36 (7): 1129-33
Dell D, Chamberlain J. Determination of molsidomine in plasma by high-performance liquid column chromatography. J Chromatogr 1978; 146 (3): 465-73
Streel B, Ceccato A, Peerboom C, et al. Determination of molsidomine and its active metabolite in human plasma using liquid chromatography with tandem mass spectrometric detection. J Chromatogr A 1998; 819 (1-2): 113-23
Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15 (6): 657-80
Herchuelz A. Bioequivalence assessment and the conduct of bioequivalence trials: a European point of view. Eur J Drug Metab Pharmacokinet 1996; 21 (2): 149-52
Marzo A, Balant LP. Bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittel Forschung 1995; 45 (2): 109-15
The EMEA (Human Medicines Evaluation Unit) Committee for Proprietary Medicinal Products. Note for guidance on quality of modified release products: EMEA; 1999 Jul 29. CPMP/QWP/604/96
Langtry HD, Spencer CM. Nisoldipine coat-core: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease. Drugs 1997; 53 (5): 867-84
Beudeker HJ, van der Velden JW, van der Aar EM. Interaction profile and tolerability of barnidipine. Int J Clin Pract Suppl 2000; (114): 36-40
Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994; 26 (5): 335-46
Power JM, Morgan DJ, McLean AJ. Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Biopharm Drug Dispos 1995; 16 (7): 579-89
Ibrahim TM, Unger PH, Sobolski J, et al. Hemodynamic effects of SIN-1 in acute left heart failure. Cardiovasc Drugs Ther 1989; 3 (4): 557-61
Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37 (3): 213-55
Kosoglou T, Kazierad DJ, Schentag JJ, et al. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. J Clin Pharmacol 1995; 35 (2): 151-8
Rakhit A, Kochak GM, Tipnis V, et al. Pharmacokinetics of pentopril in the elderly. Br J Clin Pharmacol 1987; 24 (3): 351-7
Williams PE, Brown AN, Rajaguru S, et al. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol 1989; 27 Suppl. 2: 211S-5S
Sowinski KM, Forrest A, Wilton JH et al. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. J Clin Pharmacol 1995; 35 (8): 807-14
Muck W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol Ther 1996; 34 (7): 293-8
Bianchetti G, Billy S, Ascalone V, et al. Multicenter studies on the pharmacokinetic profile of prolonged release oral diltiazem (300 mg) after once a day repeated administration: influence of age. Int J Clin Pharmacol Ther 1996; 34 (5): 195-201
Messin R, Fenyvesi T, Carreer-Bruhwyler F, et al. A pilot double-blind randomized placebo-controlled study of molsidomine 16mg once-a-day in patients suffering from stable agina pectoris: correlation between efficacy and over time plasma concentrations. Eur J Clin Pharmacol 2003; 59 (3): 227-32
Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol. In press
Messin R, Career-Bruhwyler F, Dubois C, et al. Age-dependent therapeutic effects of once-daily molsidomme used as an add-on treatment in patients with stable angina pectoris. Heart Drug. In press
